Andere Sprachen Solid Biosciences Inc.

Aktien

A3DXEC

US83422E2046

SLDB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
9,54 ^USD	+7,55 %		+8,78 %	+55,37 %

01.04.	SGT-003 von Solid Biosciences erhält von der US FDA das Label für seltene pädiatrische Erkrankungen	MT
01.04.	Solid Biosciences Inc. erhält von der FDA den Status einer seltenen pädiatrischen Erkrankung für den Gentherapiekandidaten SGT-003 für Duchenne-Muskeldystrophie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.04.
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	01.04.
Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	01.04.
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	01.04.
Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	01.04.
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium	27.03.
North American Morning Briefing : Inflation -2-	15.03.
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results	13.03.
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13.03.
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD	07.03.
Solid Biosciences Inc. Announces Licensing Agreement with Armatus Bio for the Use of Aav-Slb101, A Proprietary, Muscle-Targeted Capsid, in the Development of an Rnai Therapy to Treat Fshd	07.03.
Solid Biosciences to Participate at Upcoming Investor Conferences	06.03.
Solid Biosciences Gets FDA Orphan Drug Designation for Duchenne Drug Candidate	16.01.
Solid Biosciences Gets Orphan Drug Designation for SGT-003	16.01.
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	16.01.
Top Midday Gainers	09.01.
Solid Biosciences Shares Surge After Revealing $109 Million Private Placement	09.01.
Solid Biosciences Announces $109 Million Private Placement	08.01.
Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors	08.01.
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference	04.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Solid Biosciences Inc.

Aktien

A3DXEC

US83422E2046

SLDB

Andere Sprachen

Filter